May 20, 2014 by Brian Orelli, PhDBiotech Tweet of the Week: Share BuybacksShould Gilead Sciences, Celgene, Biogen Idec, and Amgen buy back shares or use their cash elsewhere?
May 19, 2014 by Brian Orelli, PhDBiotech 101: Breakthrough TherapyBreakthrough Therapy designation is a term that investors in drugmakers such as Novartis, Medivation, and Sarepta Therapeutics need to understand.
May 19, 2014 by Brian Orelli, PhDOrphan Drugs in Trouble?Aegerion Pharmaceuticals' Juxtapid hits a rough spot. Is Sanofi's and Isis Pharmaceuticals' Kynamro to blame?
May 19, 2014 by Brian Orelli, PhDAstraZeneca's Fishy FDA ApprovalAstraZeneca's Epanova joins the list of omega-3 fish oil drugs that includes GlaxoSmithKline's Lovaza and Amarin's Vascepa.
May 19, 2014 by Brian Orelli, PhDBiotech Tweet of the Week: Investing in Moldy PizzaInvesting in something that might not work is O.K. as shareholders of Aeterna Zentaris, Keryx Biopharmaceuticals, and MannKind can attest.
May 18, 2014 by Brian Orelli, PhDBiotech of the Week: Ariad Pharmaceuticals, Inc.After high hopes, it doesn't look like Ariad Pharmaceuticals' Iclusig will be able to compete with leukemia drugs from Novartis and Bristol-Myers Squibb.
May 16, 2014 by Brian Orelli, PhDDrug-Pricing Rhetoric: Should Investors be Worried?Biogen Idec's Avonex and Novartis' Gleevec have more than doubled in price since 2007. And payers are questioning the high price of Gilead Science's Sovaldi.
May 15, 2014 by Brian Orelli, PhDBiotech Bad News BuysThe Biotech Banter crew breaks down recent drops in Seattle Genetics, Pharmacyclics, and Endocyte.
May 15, 2014 by Brian Orelli, PhDPipeline Breakdown: Merck & Co. Inc.Merck is competing against Bristol-Meyers Squibb in immuno-oncology, but taking an "if you can't beat 'em join 'em" approach against Gilead Sciences in hepatitis C.
May 14, 2014 by Brian Orelli, PhDASCO Abstracts: Big Pharma EditionBristol-Myers Squibb, Merck, AstraZeneca, and Eli Lilly present data at the cancer confab.
May 13, 2014 by Brian Orelli, PhDASCO Abstracts: Bristol-Myers Squibb's and Merck's Immuno-Oncology DrugsBristol-Myers Squibb's nivolumab and Merck's MK-3475 take center stage for the second year running.
May 13, 2014 by Brian Orelli, PhDThe ASCO Abstracts Are ComingFools preview data from AstraZeneca, Johnson & Johnson, Pharmacyclics, GlaxoSmithKline, and Incyte at the upcoming cancer meeting.
May 6, 2014 by Brian Orelli, PhDThis Billionaire Hates Your Drugmaker (Unless It's the One He's Helping)William Ackman apparently doesn't like Gilead Sciences, Pfizer, or Merck,but he's hot on Valeant Pharmaceuticals, which he's helping in order to buy Allergan.
May 5, 2014 by Brian Orelli, PhDBiotech Tweet of the Week: Do Your Due DiligenceInvestors need to explore all their options -- look at VIVUS, Orexigen, and Arena Pharmaceuticals, for instance -- before investing in a biotech company.
May 5, 2014 by Brian Orelli, PhDBiotech of the Week: Opko Health Inc.Opko Health competes with Laboratory Corporation of America and Quest Diagnostics on the diagnostics side and is partnered with Tesaro on the therapeutics side.
May 5, 2014 by Brian Orelli, PhDBiotech 101: Valuing Binary EventsSarepta Therapeutics, Revance Therapeutics, and Cytokinetics saw big moves recently; MannKind and Orexigen could be next.
May 1, 2014 by Brian Orelli, PhDPharma M&A: It's BackNovartis, GlaxoSmithKline, and Eli Lilly do a three-way trade, while Merck is reportedly offloading its consumer health-care unit.
Apr 29, 2014 by Brian Orelli, PhDBiotech Tweet of the Week: Will Icahn Attack Gilead?Gilead Sciences could follow in the footsteps of MedImmune (sold to AstraZeneca), Genzyme (sold to Sanofi), and ImClone (sold to Eli Lilly).
Apr 28, 2014 by Brian Orelli, PhDPfizer Could Buy These 30 Biotechs Instead of One AstraZeneca (but It Won't)Buying smaller companies would be a better deal for Pfizer than AstraZeneca.
Apr 28, 2014 by Brian Orelli, PhDBiotech of the Week: Chelsea Therapeutics International Ltd.A breakdown of what Chelsea Therapeutics has and where it's going.
